Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSP NASDAQ:IRMD NASDAQ:SMLR NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$42.74+0.7%$48.05$38.91▼$147.03$1.22B0.731.04 million shs1.05 million shsIRMDiRadimed$93.60-2.8%$90.89$55.11▼$107.90$1.23B0.91148,930 shs175,213 shsSMLRSemler Scientific$20.33-4.9%$19.24$14.89▼$50.44$310.74M1.32895,814 shs1.62 million shsTNDMTandem Diabetes Care$16.60+5.1%$17.75$9.98▼$29.65$1.08B1.582.91 million shs1.93 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems+0.80%+3.49%+1.97%-27.11%-67.73%IRMDiRadimed-2.76%+0.57%+9.77%-6.11%+55.97%SMLRSemler Scientific0.00%0.00%0.00%0.00%-35.91%TNDMTandem Diabetes Care+5.06%-14.17%+17.65%-23.11%-22.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$42.74+0.7%$48.05$38.91▼$147.03$1.22B0.731.04 million shs1.05 million shsIRMDiRadimed$93.60-2.8%$90.89$55.11▼$107.90$1.23B0.91148,930 shs175,213 shsSMLRSemler Scientific$20.33-4.9%$19.24$14.89▼$50.44$310.74M1.32895,814 shs1.62 million shsTNDMTandem Diabetes Care$16.60+5.1%$17.75$9.98▼$29.65$1.08B1.582.91 million shs1.93 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems+0.80%+3.49%+1.97%-27.11%-67.73%IRMDiRadimed-2.76%+0.57%+9.77%-6.11%+55.97%SMLRSemler Scientific0.00%0.00%0.00%0.00%-35.91%TNDMTandem Diabetes Care+5.06%-14.17%+17.65%-23.11%-22.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.05Hold$81.8491.50% UpsideIRMDiRadimed 3.00Buy$120.0028.21% UpsideSMLRSemler Scientific 2.75Moderate Buy$75.33270.55% UpsideTNDMTandem Diabetes Care 2.48Hold$29.8479.77% UpsideCurrent Analyst Ratings BreakdownLatest SMLR, IRMD, INSP, and TNDM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/10/2026TNDMTandem Diabetes Care Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/1/2026TNDMTandem Diabetes Care Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Overweight$21.00 ➝ $27.005/28/2026TNDMTandem Diabetes Care CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$22.00 ➝ $17.005/27/2026TNDMTandem Diabetes Care The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.005/26/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026INSPInspire Medical Systems Summit RedstoneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$39.005/22/2026INSPInspire Medical Systems Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Underperform$39.005/20/2026IRMDiRadimed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/18/2026TNDMTandem Diabetes Care Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $25.005/13/2026INSPInspire Medical Systems Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$911.98M1.35$2.88 per share14.82$26.88 per share1.59IRMDiRadimed$83.81M14.27$1.81 per share51.79$7.44 per share12.58SMLRSemler Scientific$36.96M8.41$4.48 per share4.54$24.90 per share0.82TNDMTandem Diabetes Care$1.01B1.12N/AN/A$2.29 per share7.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$145.42M$4.499.5229.474.3814.33%10.35%8.81%8/3/2026 (Estimated)IRMDiRadimed$22.48M$1.8351.15N/AN/A27.36%24.48%21.25%7/30/2026 (Estimated)SMLRSemler Scientific$40.90M$2.787.31N/AN/A130.80%34.21%25.58%N/ATNDMTandem Diabetes Care-$204.71M-$1.40N/A415.00N/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)Latest SMLR, IRMD, INSP, and TNDM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026TNDMTandem Diabetes Care-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million5/4/2026Q1 2026INSPInspire Medical Systems-$0.2753$0.10+$0.3753-$0.39$200.04 million$204.58 million5/1/2026Q1 2026IRMDiRadimed$0.46$0.49+$0.03$0.45$21.32 million$21.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/AIRMDiRadimed$0.800.85%N/A43.72%1 YearsSMLRSemler ScientificN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ALatest SMLR, IRMD, INSP, and TNDM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026IRMDiRadimedquarterly$0.200.93%5/15/20265/15/20265/29/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A6.344.48IRMDiRadimedN/A7.136.15SMLRSemler Scientific0.211.971.95TNDMTandem Diabetes Care4.543.583.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%IRMDiRadimed92.34%SMLRSemler Scientific49.37%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems2.20%IRMDiRadimed36.80%SMLRSemler Scientific16.40%TNDMTandem Diabetes Care2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,33328.81 million28.18 millionOptionableIRMDiRadimed11012.78 million8.08 millionOptionableSMLRSemler Scientific12015.29 million12.78 millionNot OptionableTNDMTandem Diabetes Care2,50068.53 million67.09 millionOptionableSMLR, IRMD, INSP, and TNDM HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 10 at 2:28 AM | americanbankingnews.comTandem Diabetes: Neutral Stance Maintained as Mobi Tubeless Opportunity Balances Execution Risks; $25 Price Target UnchangedJune 9, 2026 | tipranks.comTandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comHow The Investment Story For Tandem Diabetes Care (TNDM) Is Evolving Without New Analyst TargetsJune 7, 2026 | finance.yahoo.comTandem insulin pumps cleared in EU for expanded indicationsJune 6, 2026 | seekingalpha.comWall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?June 5, 2026 | zacks.comTandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During PregnancyJune 5, 2026 | businesswire.comReasons to Add Tandem Diabetes Stock to Your Portfolio Right NowJune 4, 2026 | zacks.com3 Stocks to Invest in as Broker Rating Upgrades Signal UpsideJune 4, 2026 | zacks.comTandem: Upgrading To Hold On A High-Stakes Pivot StoryJune 4, 2026 | seekingalpha.comWells Fargo Upgrade Highlights Tandem Diabetes Care Pharmacy And Pump ShiftJune 3, 2026 | finance.yahoo.comTandem Diabetes Valuation: Is 1.1x Sales a Buy?June 3, 2026 | zacks.comTNDM Stock: What to Know About Tandem's 2026 ResetJune 2, 2026 | zacks.comTandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Score of 62 Tells InvestorsMay 28, 2026 | gurufocus.comTandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed?May 24, 2026 | finance.yahoo.comSilver Economy Investing: Why the Healthcare Giants Are in FocusMay 19, 2026 | zacks.comTandem Diabetes’s Q1 earnings call: Our top 5 analyst questionsMay 14, 2026 | msn.comTNDM stock down following Q1 earnings & revenue beat, gross margin upMay 14, 2026 | msn.comTNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin UpMay 14, 2026 | zacks.comTandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMLR, IRMD, INSP, and TNDM Company DescriptionsInspire Medical Systems NYSE:INSP$42.74 +0.30 (+0.70%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$42.71 -0.02 (-0.05%) As of 06/12/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.iRadimed NASDAQ:IRMD$93.60 -2.66 (-2.76%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$93.56 -0.04 (-0.05%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Semler Scientific NASDAQ:SMLRSemler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.Tandem Diabetes Care NASDAQ:TNDM$16.60 +0.80 (+5.06%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$16.60 +0.00 (+0.03%) As of 06/12/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
